You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePiretanide
Accession NumberDB02925  (EXPT03308)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArelixNot Available
PiretanideJAN
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIDQ6KK6GV93
CAS number55837-27-9
WeightAverage: 362.4
Monoisotopic: 362.093642386
Chemical FormulaC17H18N2O5S
InChI KeyUJEWTUDSLQGTOA-UHFFFAOYSA-N
InChI
InChI=1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
IUPAC Name
4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic acid
SMILES
NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Solute carrier family 12 member 1Proteinunknown
inhibitor
HumanQ13621 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Piretanide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Piretanide.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Piretanide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Piretanide.Experimental, Illicit
AceclofenacAceclofenac may decrease the diuretic activities of Piretanide.Approved
AcetovanilloneAcetovanillone may decrease the diuretic activities of Piretanide.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Piretanide.Approved, Vet Approved
AclarubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Aclarubicin.Investigational
AdapaleneAdapalene may decrease the diuretic activities of Piretanide.Approved
AlclometasoneAlclometasone may increase the hypokalemic activities of Piretanide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Piretanide.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Piretanide.Approved, Illicit
AllopurinolThe risk or severity of adverse effects can be increased when Piretanide is combined with Allopurinol.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Piretanide.Experimental, Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Piretanide.Approved
AmikacinThe risk or severity of adverse effects can be increased when Piretanide is combined with Amikacin.Approved, Vet Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Piretanide.Approved
AmrubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Amrubicin.Approved, Investigational
AnecortaveAnecortave may increase the hypokalemic activities of Piretanide.Investigational
AnisodamineAnisodamine may decrease the diuretic activities of Piretanide.Investigational
annamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with annamycin.Investigational
AntipyrineAntipyrine may decrease the diuretic activities of Piretanide.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Piretanide is combined with Anvirzel.Investigational
ApramycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Apramycin.Experimental, Vet Approved
ApremilastApremilast may decrease the diuretic activities of Piretanide.Approved, Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Piretanide is combined with Arbekacin.Approved
ArbutamineArbutamine may increase the hypokalemic activities of Piretanide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
Atracurium besylatePiretanide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the diuretic activities of Piretanide.Withdrawn
AzelastineAzelastine may decrease the diuretic activities of Piretanide.Approved
BalsalazideBalsalazide may decrease the diuretic activities of Piretanide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Piretanide.Approved
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Piretanide.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Piretanide.Approved, Investigational
BenazeprilPiretanide may increase the hypotensive activities of Benazepril.Approved, Investigational
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Piretanide.Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
Betulinic AcidBetulinic Acid may decrease the diuretic activities of Piretanide.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Piretanide.Experimental, Illicit, Withdrawn
BromfenacBromfenac may decrease the diuretic activities of Piretanide.Approved
BucillamineBucillamine may decrease the diuretic activities of Piretanide.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Piretanide.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Piretanide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Piretanide.Approved, Illicit, Vet Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Piretanide.Approved
CandoxatrilPiretanide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilPiretanide may increase the hypotensive activities of Captopril.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Piretanide.Illicit, Vet Approved
CarprofenCarprofen may decrease the diuretic activities of Piretanide.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the diuretic activities of Piretanide.Experimental
CelecoxibCelecoxib may decrease the diuretic activities of Piretanide.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Piretanide.Approved, Investigational
ChloroquineChloroquine may decrease the diuretic activities of Piretanide.Approved, Vet Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Piretanide.Approved, Investigational
CilazaprilPiretanide may increase the hypotensive activities of Cilazapril.Approved
Cisatracurium besylatePiretanide may decrease the neuromuscular blocking activities of Cisatracurium besylate.Approved
CisplatinPiretanide may increase the nephrotoxic activities of Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Piretanide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Piretanide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Piretanide.Approved
ClonixinClonixin may decrease the diuretic activities of Piretanide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Piretanide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Piretanide.Approved
CurcuminCurcumin may decrease the diuretic activities of Piretanide.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Piretanide.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the diuretic activities of Piretanide.Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Daunorubicin.Approved
DecamethoniumPiretanide may decrease the neuromuscular blocking activities of Decamethonium.Approved
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Piretanide.Investigational
dersalazinedersalazine may decrease the diuretic activities of Piretanide.Investigational
DeslanosideThe risk or severity of adverse effects can be increased when Piretanide is combined with Deslanoside.Approved
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Piretanide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Piretanide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Piretanide.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Piretanide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Piretanide.Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Piretanide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Piretanide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Piretanide.Approved
DiclofenacDiclofenac may decrease the diuretic activities of Piretanide.Approved, Vet Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Piretanide.Approved
DiflunisalDiflunisal may decrease the diuretic activities of Piretanide.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Piretanide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Piretanide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Piretanide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Piretanide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Piretanide.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Dihydrostreptomycin.Vet Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Piretanide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Piretanide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Piretanide.Approved
DofetilidePiretanide may increase the QTc-prolonging activities of Dofetilide.Approved
Domoic AcidPiretanide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chloridePiretanide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Doxorubicin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Piretanide.Investigational
DroxicamDroxicam may decrease the diuretic activities of Piretanide.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Piretanide.Approved, Investigational
DuvelisibDuvelisib may decrease the diuretic activities of Piretanide.Investigational
E6201E6201 may decrease the diuretic activities of Piretanide.Investigational
EbselenEbselen may decrease the diuretic activities of Piretanide.Investigational
EnalaprilPiretanide may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatPiretanide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Piretanide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
EpirizoleEpirizole may decrease the diuretic activities of Piretanide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Epirubicin.Approved
EquileninEquilenin may increase the hypokalemic activities of Piretanide.Experimental
EquilinEquilin may increase the hypokalemic activities of Piretanide.Approved
EstroneEstrone may increase the hypokalemic activities of Piretanide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Piretanide.Approved
EtanerceptEtanercept may decrease the diuretic activities of Piretanide.Approved, Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Piretanide.Approved, Illicit
EtodolacEtodolac may decrease the diuretic activities of Piretanide.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the diuretic activities of Piretanide.Approved
EtoricoxibEtoricoxib may decrease the diuretic activities of Piretanide.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Piretanide.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Piretanide.Approved
exisulindexisulind may decrease the diuretic activities of Piretanide.Investigational
FenbufenFenbufen may decrease the diuretic activities of Piretanide.Approved
FenoprofenFenoprofen may decrease the diuretic activities of Piretanide.Approved
FenoterolFenoterol may increase the hypokalemic activities of Piretanide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Piretanide.Approved, Illicit, Investigational, Vet Approved
FloctafenineFloctafenine may decrease the diuretic activities of Piretanide.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Piretanide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Piretanide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Piretanide.Approved, Investigational
FlunixinFlunixin may decrease the diuretic activities of Piretanide.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Piretanide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Piretanide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Piretanide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Piretanide.Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Piretanide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Piretanide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Piretanide.Approved
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Piretanide.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Piretanide.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Piretanide.Approved
FormestaneFormestane may increase the hypokalemic activities of Piretanide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Piretanide.Approved
FosinoprilPiretanide may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Piretanide.Approved
FramycetinThe risk or severity of adverse effects can be increased when Piretanide is combined with Framycetin.Approved
Gallamine TriethiodidePiretanide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe risk or severity of adverse effects can be increased when Piretanide is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Piretanide is combined with GENTAMICIN C1A.Experimental
HE3286HE3286 may increase the hypokalemic activities of Piretanide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Piretanide.Approved, Illicit
HigenamineHigenamine may decrease the diuretic activities of Piretanide.Investigational
HMPL-004HMPL-004 may decrease the diuretic activities of Piretanide.Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Piretanide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Piretanide.Approved, Illicit
Hygromycin BThe risk or severity of adverse effects can be increased when Piretanide is combined with Hygromycin B.Vet Approved
IbuprofenIbuprofen may decrease the diuretic activities of Piretanide.Approved
IbuproxamIbuproxam may decrease the diuretic activities of Piretanide.Withdrawn
IcatibantIcatibant may decrease the diuretic activities of Piretanide.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Idarubicin.Approved
ImidaprilPiretanide may increase the hypotensive activities of Imidapril.Investigational
IndacaterolIndacaterol may increase the hypokalemic activities of Piretanide.Approved
IndomethacinIndomethacin may decrease the diuretic activities of Piretanide.Approved, Investigational
IndoprofenIndoprofen may decrease the diuretic activities of Piretanide.Withdrawn
INNO-206The risk or severity of adverse effects can be increased when Piretanide is combined with INNO-206.Investigational
IsoetarineIsoetarine may increase the hypokalemic activities of Piretanide.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Piretanide.Approved
IsoxicamIsoxicam may decrease the diuretic activities of Piretanide.Withdrawn
IstaroximeIstaroxime may increase the hypokalemic activities of Piretanide.Investigational
IvabradinePiretanide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Kanamycin.Approved, Vet Approved
KebuzoneKebuzone may decrease the diuretic activities of Piretanide.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Piretanide.Approved
KetoprofenKetoprofen may decrease the diuretic activities of Piretanide.Approved, Vet Approved
KetorolacKetorolac may decrease the diuretic activities of Piretanide.Approved
LeflunomideLeflunomide may decrease the diuretic activities of Piretanide.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Piretanide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Piretanide.Approved
LicoriceLicorice may increase the hypokalemic activities of Piretanide.Approved
LisinoprilPiretanide may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the diuretic activities of Piretanide.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Piretanide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Piretanide.Illicit
LornoxicamLornoxicam may decrease the diuretic activities of Piretanide.Approved
LoxoprofenLoxoprofen may decrease the diuretic activities of Piretanide.Approved
LumiracoxibLumiracoxib may decrease the diuretic activities of Piretanide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Piretanide.Approved
MasoprocolMasoprocol may decrease the diuretic activities of Piretanide.Approved
ME-609ME-609 may increase the hypokalemic activities of Piretanide.Investigational
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Piretanide.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Piretanide.Approved
Mefenamic acidMefenamic acid may decrease the diuretic activities of Piretanide.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Piretanide.Vet Approved
MeloxicamMeloxicam may decrease the diuretic activities of Piretanide.Approved, Vet Approved
MesalazineMesalazine may decrease the diuretic activities of Piretanide.Approved
MetamizoleMetamizole may decrease the diuretic activities of Piretanide.Withdrawn
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Piretanide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Piretanide.Approved, Illicit
MethotrexateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Methotrexate.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
MetocurinePiretanide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodidePiretanide may decrease the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetrizamideThe risk or severity of adverse effects can be increased when Piretanide is combined with Metrizamide.Approved
MivacuriumPiretanide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineMizoribine may decrease the diuretic activities of Piretanide.Investigational
MoexiprilPiretanide may increase the hypotensive activities of Moexipril.Approved
MometasoneMometasone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Piretanide.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Piretanide.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Piretanide.Approved
NabumetoneNabumetone may decrease the diuretic activities of Piretanide.Approved
NafamostatNafamostat may decrease the diuretic activities of Piretanide.Investigational
NaftifineNaftifine may decrease the diuretic activities of Piretanide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Piretanide.Approved
NaproxenNaproxen may decrease the diuretic activities of Piretanide.Approved, Vet Approved
NCX 1022NCX 1022 may increase the hypokalemic activities of Piretanide.Investigational
NCX 4016NCX 4016 may decrease the diuretic activities of Piretanide.Investigational
NeamineThe risk or severity of adverse effects can be increased when Piretanide is combined with Neamine.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinPiretanide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the diuretic activities of Piretanide.Approved
NetilmicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Netilmicin.Approved
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Piretanide.Approved
NimesulideNimesulide may decrease the diuretic activities of Piretanide.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the diuretic activities of Piretanide.Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Piretanide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Piretanide.Approved, Illicit
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Piretanide.Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Piretanide.Approved
OlopatadineOlopatadine may decrease the diuretic activities of Piretanide.Approved
OlsalazineOlsalazine may decrease the diuretic activities of Piretanide.Approved
OmapatrilatPiretanide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Piretanide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Piretanide.Approved
OrgoteinOrgotein may decrease the diuretic activities of Piretanide.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Piretanide is combined with Ouabain.Approved
OxaprozinOxaprozin may decrease the diuretic activities of Piretanide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Piretanide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Piretanide.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Piretanide.Withdrawn
PancuroniumPiretanide may decrease the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Piretanide.Approved
ParecoxibParecoxib may decrease the diuretic activities of Piretanide.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Paromomycin.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Piretanide.Approved, Vet Approved
PerindoprilPiretanide may increase the hypotensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Piretanide.Approved
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Piretanide.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Piretanide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Piretanide.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the diuretic activities of Piretanide.Approved, Investigational
PipecuroniumPiretanide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Pirarubicin.Investigational
PirbuterolPirbuterol may increase the hypokalemic activities of Piretanide.Approved
PirfenidonePirfenidone may decrease the diuretic activities of Piretanide.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Piretanide.Investigational
PiroxicamPiroxicam may decrease the diuretic activities of Piretanide.Approved, Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Plicamycin.Approved, Withdrawn
PrasteronePrasterone may increase the hypokalemic activities of Piretanide.Approved, Nutraceutical
PrednicarbatePrednicarbate may increase the hypokalemic activities of Piretanide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Piretanide.Experimental
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Piretanide.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Piretanide.Approved
PropacetamolPropacetamol may decrease the diuretic activities of Piretanide.Approved
PTC299PTC299 may decrease the diuretic activities of Piretanide.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Puromycin.Experimental
PyrantelPiretanide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinaprilPiretanide may increase the hypotensive activities of Quinapril.Approved, Investigational
RamiprilPiretanide may increase the hypotensive activities of Ramipril.Approved
RapacuroniumPiretanide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Piretanide.Approved
RescinnaminePiretanide may increase the hypotensive activities of Rescinnamine.Approved
ResveratrolResveratrol may decrease the diuretic activities of Piretanide.Experimental, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Ribostamycin.Approved
RimexoloneRimexolone may increase the hypokalemic activities of Piretanide.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Piretanide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Piretanide.Approved
RocuroniumPiretanide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the diuretic activities of Piretanide.Investigational, Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
SalicylamideSalicylamide may decrease the diuretic activities of Piretanide.Approved
Salicylic acidSalicylic acid may decrease the diuretic activities of Piretanide.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Piretanide.Approved
SalsalateSalsalate may decrease the diuretic activities of Piretanide.Approved
SeratrodastSeratrodast may decrease the diuretic activities of Piretanide.Approved, Investigational
SisomicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Sisomicin.Investigational
SP1049CThe risk or severity of adverse effects can be increased when Piretanide is combined with SP1049C.Investigational
SpectinomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Spectinomycin.Approved, Vet Approved
SpiraprilPiretanide may increase the hypotensive activities of Spirapril.Approved
SRT501SRT501 may decrease the diuretic activities of Piretanide.Investigational
StreptomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Streptomycin.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Piretanide is combined with Streptozocin.Approved
SuccinylcholinePiretanide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Piretanide.Approved, Investigational
SulfasalazineSulfasalazine may decrease the diuretic activities of Piretanide.Approved
SulindacSulindac may decrease the diuretic activities of Piretanide.Approved
SulpirideThe risk or severity of adverse effects can be increased when Piretanide is combined with Sulpiride.Approved
SuprofenSuprofen may decrease the diuretic activities of Piretanide.Approved, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Piretanide.Approved
TemocaprilPiretanide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the diuretic activities of Piretanide.Approved
TepoxalinTepoxalin may decrease the diuretic activities of Piretanide.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Piretanide.Approved
TeriflunomideTeriflunomide may decrease the diuretic activities of Piretanide.Approved
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Piretanide.Approved
TinoridineTinoridine may decrease the diuretic activities of Piretanide.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Piretanide.Approved
TobramycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Tobramycin.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Piretanide.Approved
TolmetinTolmetin may decrease the diuretic activities of Piretanide.Approved
TopiramatePiretanide may increase the hypokalemic activities of Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Piretanide.Approved, Investigational
TrandolaprilPiretanide may increase the hypotensive activities of Trandolapril.Approved
TranilastTranilast may decrease the diuretic activities of Piretanide.Approved, Investigational
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the diuretic activities of Piretanide.Approved
TubocurarinePiretanide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the diuretic activities of Piretanide.Investigational, Withdrawn
ValrubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Valrubicin.Approved
VecuroniumPiretanide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VilanterolVilanterol may increase the hypokalemic activities of Piretanide.Approved
ZaltoprofenZaltoprofen may decrease the diuretic activities of Piretanide.Approved
ZileutonZileuton may decrease the diuretic activities of Piretanide.Approved, Investigational, Withdrawn
ZomepiracZomepirac may decrease the diuretic activities of Piretanide.Withdrawn
ZorubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Zorubicin.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Yuji Chikaraishi, Yoshihisa Matsuda, Makoto Otsuka, “Amorphous piretanide, piretanide polymorphs, process for their preparation and their use.” U.S. Patent US6096779, issued September, 1993.

US6096779
General ReferencesNot Available
External Links
ATC CodesC03CA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9907
Blood Brain Barrier+0.6318
Caco-2 permeable-0.6466
P-glycoprotein substrateNon-substrate0.5237
P-glycoprotein inhibitor INon-inhibitor0.8026
P-glycoprotein inhibitor IINon-inhibitor0.6635
Renal organic cation transporterNon-inhibitor0.7657
CYP450 2C9 substrateNon-substrate0.7067
CYP450 2D6 substrateNon-substrate0.8032
CYP450 3A4 substrateNon-substrate0.5997
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6747
Ames testNon AMES toxic0.6433
CarcinogenicityNon-carcinogens0.6985
BiodegradationNot ready biodegradable0.9786
Rat acute toxicity1.8427 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.848
hERG inhibition (predictor II)Inhibitor0.5391
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.92BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0914 mg/mLALOGPS
logP2.2ALOGPS
logP2.25ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)4.68ChemAxon
pKa (Strongest Basic)-0.62ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.93 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93.68 m3·mol-1ChemAxon
Polarizability35.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylethers
Direct ParentDiphenylethers
Alternative Parents
Substituents
  • Diphenylether
  • 1-phenylpyrrolidine
  • Diaryl ether
  • Aminobenzenesulfonamide
  • Benzenesulfonamide
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Substituted aniline
  • Dialkylarylamine
  • Benzoyl
  • Aniline
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrrolidine
  • Pyrrole
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23